

To: Transfusion Laboratory Managers, Transfusion Practitioners, Consultant Haematologists with responsibility for Blood Transfusion, Hospital Transfusion Committee Chairs

17 March 2021

CONVALESCENT PLASMA (“CCP”) IN THE MANAGEMENT OF HOSPITALISED PATIENTS WITH COVID-19

Dear Colleague,

We have received notification that a Central Alerting System (CAS) alert has been issued in relation to convalescent plasma. This follows the results from the RECOVERY trial, a randomised, controlled, open-label, adaptive platform trial, showed no significant clinical benefit from treatment with high-titre convalescent plasma in patients hospitalised with COVID-19.

<https://www.cas.mhra.gov.uk/ViewandAcknowledgment/ViewAlert.aspx?AlertID=103152>

The CAS alert advises:

- It is ... now recommended that convalescent plasma is NOT used in the management of hospitalised patients with confirmed or suspected SARS-CoV-2 infection.

The recommendation will be reviewed if further evidence becomes available including further subgroup analysis of data.

Action required

- Please continue to store any unused CCP pending further information from NHSBT.

If you have any queries regarding the content of this letter, please contact your local Hospital Customer Service Manager or Patient Blood Management Practitioner.

Dr Shubha Allard
Consultant Haematologist NHS Blood and Transplant
Clinical Director NHSBT PBM Consultants Team

Louise Sherliker
National Lead - Patient Blood Management team, NHSBT